查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138398

囊性纖維化全球市場-2022-2029

Global Cystic Fibrosis Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

主要驅動因素是患病率增加、對管道藥物的需求不斷增長、醫療保健行業對囊性纖維化治療的認識不斷提高，以及非營利組織的積極舉措。

地方和國家非營利組織的積極努力有望推動市場增長。

增長的關鍵驅動力之一是地方和國家非營利組織所做的積極工作。這些項目幫助 CF 患者。這些組織支持這些療法的研究和開發工作，並幫助改善這些患者的生活質量。例如，北美囊性纖維化會議 (NACFC) 為囊性纖維化專業人士提供了一個協作和教育論壇，以分享與 CF 治療相關的研究和開發進展。 2019 年 9 月 12 日宣布了一項為期五年的協議，根據該協議，蘇格蘭 NHS 將每年為 Orkambi 和 Symkevi 等囊性纖維化藥物提供 100,000 英鎊。因此，有利可圖的舉措正在推動市場。

此外，主要參與者正在市場上開展業務，與非營利組織合作開發新的治療方法。在臨床試驗的藥物中，Vertex 正在為 18 歲及以上具有一個 F508del 突變和一個最小 CFTR 突變或兩個 F508del 突變的 CF 患者提供 VX，這是一種下一代三聯療法。一項 II 期試驗（NCT03912233） - 121+tezacaftor+VX-561（deutivacaftor）已經完成。因此，從上述陳述來看，預計市場將在預測期內受到驅動。

限制

但是，由於 CF 是一種罕見疾病，因此可用信息有限，因此必須進行廣泛的研究。 CF研發成本非常高，導致高端產品價格偏高。飆升的藥物和治療成本是抑制囊性纖維化市場增長的因素之一。

行業分析

囊性纖維化市場根據各種行業因素（包括未滿足的需求、定價分析、供應鏈分析和監管分析）對市場進行深入分析。

全球囊性纖維化市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁的組成。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 地方和國家非營利組織的積極努力有望推動市場增長。
    • 限制因素
      • 預計飆升的藥物和治療成本將阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五種力量
  • 未滿足的需求
  • 供應鏈
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按藥物類別

  • CFTR 調製器
    • Kalydeco (依巴咖啡醇)
    • Orcambi（Luma 封面/Iba 封面）
    • Symdeko (Tezakaftor/Ivacaftor)
    • Torikafuta (Elexa Kafta/Teza Kafta/Iba Kafta)
  • 胰□補充劑
  • 粘液溶解劑
  • 支氣管擴張劑

第 8 章給藥途徑

  • 口語
  • 吸入
  • 腸胃外

第 9 章按分銷渠道

  • 醫院藥房
  • 在線藥店
  • 零售藥房

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • Vertex Pharmaceuticals Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Gilead sciences
  • Allergan
  • AstraZeneca
  • Alcresta Therapeutics Inc.
  • Merck & Co. Inc
簡介目錄
Product Code: DMPH1603

Market Overview

Cystic Fibrosis Market is estimated to reach at a CAGR of 13.2% during the forecast period (2022-2029).

Cystic fibrosis (CF) is a life-limiting autosomal recessive genetic disorder that causes severe damage to secretory glands of the body, like the lungs, pancreas, liver, and intestines. It is more common in the lungs. The disease is caused by the mutation of a gene that encodes a chloride-conducting transmembrane channel called the cystic fibrosis transmembrane conductance regulator (CFTR).

Market Dynamics

The major driving forces are the increasing prevalence, rising demand for pipeline drugs, increasing awareness among the healthcare fraternity about cystic fibrosis therapy, and favorable initiatives undertaken by nonprofit organizations.

Favorable initiatives taken by regional and national nonprofit organizations are expected to drive market growth.

One of the primary factors driving growth is the positive actions performed by regional and national nonprofit groups. These projects assist CF patients. These organizations aid in the research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, the North American Cystic Fibrosis Conference (NACFC) provides a collaborative and educational forum for cystic fibrosis professionals to share advances in R&D related to CF therapeutics. Also, a five-year deal was announced on 12 September 2019, according to which the NHS Scotland has decided to provide £ 100,000 per year for cystic fibrosis drugs like Orkambi and Symkevi. Thus, favorable initiatives are driving the market.

Moreover, the key players are operating in the market, collaborating with nonprofit organizations to develop novel therapeutics for the treatment. Some of the drugs in clinical trials are Vertex has completed one Phase II study (NCT03912233) of their next-generation triple combination therapy, VX-121 + tezacaftor + VX-561 (deutivacaftor), in CF patients aged 18 and older with one F508del mutation and one minimal function CFTR mutation, or two F508del mutations. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

However, due to the limited information available, extensive research is essential as CF is a rare disease. The research and development cost for CF is very high, leading to the enormous prices of the end products. The high cost of drugs and treatment is one of the factors that hamper the growth of the cystic fibrosis market.

Industry Analysis

The cystic fibrosis market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

CFTR modulators segment is expected to hold the largest market share in the cystic fibrosis market.

The CFTR modulators segment accounted for the largest market share in 2021. This is owing to the increased number of US FDA approvals of the drugs. For instance, Ivacaftor (KALYDECO), a CFTR modulator introduced by Vertex pharmaceuticals, was developed in conjunction with the Cystic fibrosis Foundation (CFF). Also, on June 21, 2019, the US FDA approved SYMDEKO (tezacaftor/ivacaftor and ivacaftor) of Vertex pharmaceuticals to treat Cystic fibrosis in children ages 6-11 years with specific mutations in the CFTR gene. Moreover, On Apr. 19, 2022, The Cystic Fibrosis Foundation invested $5 million in Sionna Therapeutics company. The company is focused exclusively on developing cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a type of therapy that treats the underlying cause of CF. Sionna is developing a pipeline of potential modulators that could benefit people with the most common CF-causing mutation, F508del, and may eventually offer an alternative to currently approved CFTR modulators. The novel modulators target NBD1, the gene region where the F508del mutation occurs. No modulator currently on the market targets NBD1. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global cystic fibrosis market.

North America accounted for the highest revenue share in 2021. The rising prevalence of cystic fibrosis and the presence of government initiatives are the factors to drive in the forecast period. For instance, according to the cystic fibrosis foundation (CFF), there are close to 40,000 children and adults living with cystic fibrosis in the United States (and an estimated 105,000 people have been diagnosed with CF across 94 countries), and CF can affect people of every racial and ethnic group. According to the CFF's national patient registry, the median age of a person with CF is currently 33.4 years. The average life expectancy of CF patients has increased significantly compared to the patients 30 years back. Thus, the increasing prevalence of CF has boosted North America's share in the global cystic fibrosis market.

Furthermore, Hopkins University and Medicine researchers developed a novel treatment for a pathogen in December 2020. Mycobacterium abscesses are a pathogen that is drug-resistant and harmful to persons with lung diseases or cystic fibrosis. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the cystic fibrosis market are Vertex Pharmaceuticals Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd, Gilead Sciences, Allergan, AstraZeneca, Alcresta Therapeutics Inc., and Merck & Co. Inc.

Vertex Pharmaceuticals, Inc.:

Overview:

Vertex Pharmaceuticals, Inc. was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. The company discovers, develops, manufactures and commercializes small molecule drugs for patients with serious diseases. It focuses on developing and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.

Product Portfolio:

TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor): TRIKAFTA is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or another mutation that is responsive to treatment with TRIKAFTA.

The global cystic fibrosis market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Favorable initiatives taken by regional and national nonprofit organizations are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of drugs and treatment are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. CFTR modulators*
      • 7.2.1.1. Kalydeco (ivacaftor)
      • 7.2.1.2. Introduction
      • 7.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.2.1.4. Orkambi (lumacaftor/ivacaftor)
      • 7.2.1.5. Symdeko (tezacaftor/ivacaftor)
      • 7.2.1.6. Trikafta (elexacaftor/tezacaftor/ivacaftor)
  • 7.3. Pancreatic enzyme supplements
  • 7.4. Mucolytics
  • 7.5. Bronchodilators

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Inhaled
  • 8.4. Parenteral

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Vertex Pharmaceuticals Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AbbVie Inc
  • 12.3. F. Hoffmann-La Roche Ltd
  • 12.4. Novartis AG
  • 12.5. Teva Pharmaceutical Industries Ltd
  • 12.6. Gilead sciences
  • 12.7. Allergan
  • 12.8. AstraZeneca
  • 12.9. Alcresta Therapeutics Inc.
  • 12.10. Merck & Co. Inc